

1635

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: David WALLACH et al

Art Unit: 1635

Application No.: 09/155,676

Examiner: J. Epps

Filed: January 4, 1999

Washington, D.C.

For: MODULATORS OF TNF RECEPTOR ASSOCIATED FACTOR (TRAF) THE

Atty.'s Docket: WALLACH=21

Date: February 15, 2001

THE COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

Sir:

Transmitted herewith is a [X] Amendment []
in the above-identified application.

- [] Small Entity Status: Applicant(s) claim small entity status. See 37 C.F.R. §1.27.
[XX] No additional fee is required.
[] The fee has been calculated as shown below:

RECEIVED

FEB 21 2001

TECH CENTER 1600/2900

	(Col. 1)		(Col. 2)		(Col. 3)
	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO. PREVIOUSLY PAID FOR		PRESENT EXTRA EQUALS
TOTAL	* 33	MINUS	** 50		0
INDEP.	* 6	MINUS	*** 6		0
FIRST PRESENTATION OF MULTIPLE DEP. CLAIM					

ADDITIONAL FEE TOTAL

SMALL ENTITY	
RATE	ADDITIONAL FEE
x 9	\$
x 40	\$
+ 135	\$
ADDITIONAL FEE TOTAL	
\$	

OTHER THAN SMALL ENTITY	
RATE	ADDITIONAL FEE
x 18	\$
x 80	\$
+ 270	\$
TOTAL	
\$	

- * If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.
** If the "Highest Number Previously Paid for" IN THIS SPACE is less than 20, write "20" in this space.
*** If the "Highest Number Previously Paid for" IN THIS SPACE is less than 3, write "3" in this space.

The "Highest Number Previously Paid For" (total or independent) is the highest number found from the equivalent box in Col. 1 of a prior amendment or the number of claims originally filed.

[XX] Conditional Petition for Extension of Time

If any extension of time for a response is required, applicant requests that this be considered a petition therefor.

[] It is hereby petitioned for an extension of time in accordance with 37 CFR 1.136(a). The appropriate fee required by 37 CFR 1.17 is calculated as shown below:

Small Entity

Response Filed Within

- [] First - \$ 55.00
[] Second - \$ 195.00
[] Third - \$ 445.00
[] Fourth - \$ 695.00

Month After Time Period Set

Other Than Small Entity

Response Filed Within

- [] First - \$ 110.00
[] Second - \$ 390.00
[] Third - \$ 890.00
[] Fourth - \$ 1390.00

Month After Time Period Set

[] Less fees (\$) already paid for month(s) extension of time on .

[] Please charge my Deposit Account No. 02-4035 in the amount of \$.


[] Credit Card Payment Form, PTO-2038, is attached; authorizing payment in the amount of \$.

[] A check in the amount of \$ is attached (check no.).

[XX] The Commissioner is hereby authorized and requested to charge any additional fees which may be required in connection with this application or credit any overpayment to Deposit Account No. 02-4035. This authorization and request is not limited to payment of all fees associated with this communication, including any Extension of Time fee, not covered by check or specific authorization, but is also intended to include all fees for the presentation of extra claims under 37 CFR §1.16 and all patent processing fees under 37 CFR §1.17 throughout the prosecution of the case. This blanket authorization does not include patent issue fees under 37 CFR §1.18.

BROWDY AND NEIMARK

Attorneys for Applicant(s)

By: 
Roger L. Browdy
Registration No. 25,618

Facsimile: (202) 737-3528
Telephone: (202) 628-5197

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket: WALLACH=21

In re Application of:

WALLACH et al

Appln. No.: 09/155,676

Filed: January 4, 1999


For: MODULATORS OF TNF RECEPTOR)
ASSOCIATED FACTOR (TRAF),)
THEIR PREPARATION AND USE)

Art Unit: 1635

Examiner: J. Epps

Washington, D.C.

February 15, 2001



#20/G
Bill
2-23-01
RECEIVED
FEB 21 2001
TECH CENTER 1635/2001

SUPPLEMENTAL AMENDMENT

Honorable Commissioner for Patents
Washington, D.C. 20231

RECEIVED
FEB
TC 1706

Sir:

Supplementing applicants' amendment filed February
9, 2001, please further amend as follows:

IN THE CLAIMS

Replace original claims 21 and 68 with new claims 21
and 68 as follows:

21 (Twice-amended). A method for producing a
polypeptide that binds to TRAF2 and modulates the activity of
NF-κB, comprising:

growing transformed host cells in accordance with
claim 16 under conditions for the expression of an expression
product from said cells;

SUB
#1